Becton Dickinson & Company BD gravity sets (Product Name, Catalog #) 32-IN GRAV SET W/0.2 MICRON FILTER BAG ACCESS PORT SS VALVE TEXIUMTM LOW ABSORPTION, Catalog # 4030B-07T and BD GRAVITY BLOOD SET 15 DROP 180 MICRON FILTER SmartSiteTM VALVE NONVENTED, Catalog # 42081E. Recall
Hazard assessment based on recall description.
This AI-generated summary is provided for general informational purposes only and is derived from publicly available recall notices. It supplements but does not replace official agency classifications or safety instructions.
Check Your Product
According to the U.S. Food and Drug Administration (FDA)
Product
BD gravity sets (Product Name, Catalog #) 32-IN GRAV SET W/0.2 MICRON FILTER BAG ACCESS PORT SS VALVE TEXIUMTM LOW ABSORPTION, Catalog # 4030B-07T and BD GRAVITY BLOOD SET 15 DROP 180 MICRON FILTER SmartSiteTM VALVE NONVENTED, Catalog # 42081E.
Brand
Becton Dickinson & Company
Lot Codes / Batch Numbers
UDI-DI: 10885403240867, Catalog # 4030B-07T, UDI-DI: 07613203020855, Catalog # 42081E. All lots, thru expiration date July 31, 2026.
Products Sold
UDI-DI: 10885403240867, Catalog # 4030B-07T; UDI-DI: 07613203020855, Catalog # 42081E. All lots, thru expiration date July 31, 2026.
Becton Dickinson & Company is recalling BD gravity sets (Product Name, Catalog #) 32-IN GRAV SET W/0.2 MICRON FILTER BAG ACCESS PORT SS VAL due to Affected infusion sets labeled as free of DEHP actually do contain di(2-ethylhexyl) phthalate (DEHP).. Based on FDA medical device recall database.
Summary derived from FDA notice
Reason for Recall
As stated by FDA
Affected infusion sets labeled as free of DEHP actually do contain di(2-ethylhexyl) phthalate (DEHP).
Recommended Action
Per FDA guidance
BD sent initial letters for this recall on October 11, 2023. A second notification was made available to customers on November 1, 2023 providing customers with additional information related to risk and recommended customer actions. In addition, the customer notification identified one additional product code that is in scope of this advisory. BD has identified that the infusion sets listed in Appendix 1 of the customer notification contain di(2-ethylhexyl) phthalate (DEHP) and have not been labelled accordingly. This could lead to the potential risk of DEHP exposure that may have short-term and long-term harmful effects. BD recommends using DEHP-free devices when specified by drug manufacturers. For devices in-situ with patients requiring a DEHP-free treatment, BD instructs to cease use and an alternate treatment or device be sourced. BD will be updating the labelling for these devices to state Contains or presence of phthalate: DEHP. Circulate this notice to all who need to be aware within your organization and to any organization affected devices have been further distributed to. Return the customer response from to BD whether or not you have any of the impacted material. Report any issues experienced with these devices to BD as a complaint as per your normal process. Phone: (844) 823-5433, Mon Fri 8:00am and 5:00pm CT, or Email: productcomplaints@bd.com. Any adverse health consequences experienced may also be reported to the FDA's MedWatch Adverse Event Reporting program.
Verify this information on the official source
For complete details and official instructions, check the U.S. Food and Drug Administration (FDA) directly.
View official FDA recall noticePage updated: Jan 10, 2026